- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01736514
A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
October 28, 2014 updated by: Astellas Pharma Taiwan, Inc.
A Randomized, Open Label, Multicenter, Allopurinol- Controlled Study to Assess the Safety and Efficacy of Oral Febuxostat in Patients With Gout
This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design study.
Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive febuxostat, or allopurinol for subjects with gout.
Study Overview
Study Type
Interventional
Enrollment (Actual)
109
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kaohsiung, Taiwan
-
Linkou, Taiwan
-
Taichung, Taiwan
-
Taipei, Taiwan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects will also have a history or presence of gout as defined by the American College of Rheumatology (ACR) criteria
- Subject has serum urate level >= 8.0 mg/dL at the screening Visit
Exclusion Criteria:
- Female subject who is breast-feeding or pregnant
- Subject has a history of xanthinuria
- Subject who is intolerant of allopurinol, ie hypersensitivity, Steven-Johnson syndrome/topic epidermal necrolysis
- Subject who takes allopurinol > 300 mg/day and with serum urate level > 8mg/dL
- Subject who is HLA B*5801 positive
- Subject who is receiving thiazide diuretic therapy
- Subject who has secondary hyperuricemia
- Subject who requires concurrent therapy with any systemic or topical medications, prescribed or non-prescribed, containing aspirin or other salicylates (low doses of aspirin will be allowed(ie. =< 325mg/day)
- Subject who requires therapy with prednisone > 10 mg/ day during the study
- Subject who has active liver disease or hepatic dysfunction, defined as both ALT and AST > 1.5 times the upper limit of normal
- Subject who has serum creatinine >= 1.5mg/dL
- Subject who has any another significant medical condition as defined by the investigator that would interfere with the treatment, safety or compliance with the protocol (eg. A clinically significant ECG result)
- Subject who has a history of cancer (other than basal cell carcinoma of the skin) within 5 years prior to the study, or has taken any systemic cancer chemotherapy within 5 years prior to the study
- Subject who has previously participated in a clinical study in which febuxostat was administered
- Subject who has participated in another investigational trial within the 30 days prior to the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: febuxostat group
oral
|
oral
Other Names:
|
ACTIVE_COMPARATOR: allopurinol group
oral
|
oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects whose serum urate level decreases to < 6.0 mg/dL
Time Frame: week 12
|
week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent reduction in serum urate levels
Time Frame: Baseline and at week 12
|
Baseline and at week 12
|
Safety assessed by the incidence of adverse events, physical exam. and vital signs, tabo-tests and 12-lead ECG
Time Frame: Baseline and at week 12
|
Baseline and at week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Astellas Pharma Taiwan, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (ACTUAL)
February 1, 2012
Study Completion (ACTUAL)
February 1, 2012
Study Registration Dates
First Submitted
November 27, 2012
First Submitted That Met QC Criteria
November 27, 2012
First Posted (ESTIMATE)
November 29, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
October 29, 2014
Last Update Submitted That Met QC Criteria
October 28, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Metabolism, Inborn Errors
- Crystal Arthropathies
- Purine-Pyrimidine Metabolism, Inborn Errors
- Gout
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites
- Protective Agents
- Antioxidants
- Free Radical Scavengers
- Gout Suppressants
- Allopurinol
- Febuxostat
Other Study ID Numbers
- TMXALL-1001-TW
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gout
-
Ai PengRecruitingGout Flare | Intercritical Gout | Advanced Gout | Asymptomatic HyperuricemiaChina
-
AmgenCompletedUncontrolled Gout | Chronic GoutUnited States
-
Sheffield Hallam UniversityCherry Research CommitteeUnknown
-
Olatec Therapeutics LLCRecruitingArthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout AttackUnited States, Spain, France
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalNot yet recruitingAcute Gout | Gout Initiating Urico-lowering TherapyChina
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalRecruitingGout Flare | Acute GoutChina
-
AmgenCompletedGout | Chronic Uncontrolled Gout | Uncontrolled GoutUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout With Hyperuricemia in Adults
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout and Hyperuricemia
-
Guangdong Provincial Hospital of Traditional Chinese...RecruitingAcute Pain | Acupuncture | Acute Gout ArthritisChina
Clinical Trials on febuxostat
-
Bio-innova Co., LtdNot yet recruitingHealthy Subjects
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
The Affiliated Hospital of Xuzhou Medical UniversityThe First People's Hospital of XuzhouUnknown
-
University of Mississippi Medical CenterTerminatedBlood Pressure | GoutUnited States
-
Benha UniversityNew Jeddah Clinic HospitalCompletedHemodialysis Complication | Hyperuricemia
-
JW PharmaceuticalRecruitingGoutKorea, Republic of
-
Ningbo No. 1 HospitalNot yet recruitingNonalcoholic Fatty Liver DiseaseChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout and Hyperuricemia
-
AstraZenecaCompletedType 2 Diabetes | Albuminuria | HyperuricemiaUnited States
-
TakedaCompleted